INTRODUCTION {#sec1-1}
============

Essential thrombocythemia (ET) is a rare acquired myeloproliferative disorder characterized by overproduction of platelets with a tendency for thrombosis and hemorrhage.[@ref1] It is usually diagnosed in the sixth decade of life, and more commonly affects females.[@ref2] ET is often asymptomatic, but vascular occlusive events include thromboses of large arteries and veins, and microvessels that generate neurological, cardiac, or peripheral arterial disabilities.[@ref2][@ref3] The incidence of hemorrhagic complications is relatively rare.[@ref1]

As a systemic and hematological disease, ET has the potential to influence many tissues and organs, including the eye. Ocular thromboembolic complications could deteriorate vision, especially when retinal vessels are involved. Central and branch retinal vein occlusions, central retinal artery occlusion, iritis, and partial third cranial nerve palsy are the reported ocular complications of ET.[@ref4][@ref5][@ref6][@ref7][@ref8] Also neurological events related to vision such as amaurosis fugax could occur due to ET.[@ref3]

The majority of the blood coming to the eye is within the chorioretinal circulation.[@ref9] The choroid supplies blood to the outer layers of the retina and has the highest blood flow of any tissue. Hence, the choroid should be vulnerable to hematological disorders such as ET. Additionally, retinal vessels are prone to injury due to systemic hematological disorders. We hypothesized that ET may affect the choroid and retinal vessels due to ischemia, microembolism, thrombosis, or hemorrhage. Our aim was to demonstrate choroidal anatomy by measuring the subfoveal choroidal thickness (SFCT), choroidal pulsatile blood flow by measuring ocular pulse amplitude (OPA), and retinal vasculature by measuring retinal vessel caliber. To the best of our knowledge, this is the first study in the literature related to SFCT, OPA, and retinal vessel caliber measurements in patients with ET.

MATERIALS AND METHODS {#sec1-2}
=====================

In this prospective, cross-sectional, comparative study, 74 participants (37 patients in ET group and 37 age-sex-matched healthy adults in the control group) were recruited. This study was conducted in accordance with the ethical standards of the Declaration of Helsinki and was approved by the Institutional Ethical Committee.

Study population {#sec2-1}
----------------

The study group consisted of ET patients who were treated at the division of hematology. ET was diagnosed according to the criteria proposed by WHO in 2008.[@ref10] All of the patients in the study group were treated with acetylsalicylic acid. Hydroxyurea or anagrelide was also prescribed to the patients who had additional risk factors such as old age, a history of thrombosis, and platelet count over 1000 × 10^9^/L. Exclusion criteria were any ocular surgery other than uneventful phacoemulsification and any ocular disease other than age-related cataract or mild refractive errors (\<2.0 D spherical equivalent). Patients with systemic diseases such as diabetes mellitus and systemic hypertension that might affect ocular structures were also excluded.

Examination techniques {#sec2-2}
----------------------

One eye of each subject was randomly selected. All subjects underwent an ophthalmic examination including measurement of visual acuity, biomicroscopy, air-puff tonometry, indirect retinoscopy, enhanced depth optical coherence tomography (OCT), and OPA measurements. The SFCT measurements were performed with a spectral-domain OCT (Spectralis; Heidelberg Engineering, Inc., Heidelberg, Germany). The SFCT was manually measured from the outer hyperreflective line corresponding to the retina pigment epithelium to the inner surface of the sclera. The retinal arteriolar caliber (RAC) and retinal venular caliber (RVC) measurements were also performed with the OCT. The caliber of temporal retinal arterioles and venules was measured at a distance of one disc diameter from the margin of the optic disc by using caliber tools included in the (Spectralis software version 5.8; Heidelberg Engineering Inc., Heidelberg, Germany) \[[Figure 1](#F1){ref-type="fig"}\]. The mean thickness values of superior and inferior temporal retinal arterioles and venules were calculated for each eye.

![Macular enhanced depth optical coherence tomography screen of one of the patients in which the subfoveal choroidal thickness, retinal arteriole, and retinal venule caliber measurements were performed](MEAJO-23-84-g001){#F1}

The Pascal dynamic contour tonometer (Pascal DCT, Swiss Microtechnology AG, Port, Switzerland) was used for OPA and intraocular pressure (IOP) measurements. This noninvasive and contact device is attached to a slit-lamp biomicroscope, and it has an IOP sensor on its tip. The OPA is the difference between systolic and diastolic values of the pulsatile IOP. Blood platelet counts were also recorded as platelets per μL for analysis.

Data analysis {#sec2-3}
-------------

For statistical analysis, SPSS 17.0 Software for Windows (IBM Corp., New York, NY, USA) was used to analyze outcomes. A *P* \< 0.05 was considered statistically significant. The independent samples *t*-test was used for comparison of SFCT, OPA, IOP, RAC, and RVC measurements between the study group and control group. Pearson\'s correlation coefficient analysis was used to detect correlations between OPA and SFCT, platelet count and OPA, platelet count and SFCT, platelet count and IOP.

RESULTS {#sec1-3}
=======

Thirty-seven eyes of 37 ET patients (study group) and 37 eyes of 37 healthy volunteers (control group) were examined and compared. [Table 1](#T1){ref-type="table"} presents the demographic and clinical characteristics of the subjects. The participants were age and gender matched between the groups. The mean refractive error was 0.14 ± 0.46 D in the control group, and 0.25 ± 0.87 D in the study group (*P* = 0.53).

###### 

Demographic and clinical characteristics of subjects with ET and healthy control subjects
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The mean SFCT, OPA, and IO*P* values of ET patients and controls are presented in [Table 2](#T2){ref-type="table"}. There were no statistically significant differences in the parameters between the groups. There was no correlation between OPA and SFCT in both groups. The correlations between OPA and SFCT in the study group and control group were *r* = −0.06 (*P* = 0.73) and r = 0.19 (*P* = 0.26), respectively.

###### 

The SFCT, OPA, and IOP comparisons between subjects with ET and healthy control subjects
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There was no correlation between OPA and blood platelet counts (*r* = 0.03, *P* = 0.80) \[[Figure 2a](#F2){ref-type="fig"}\]. There was no correlation between SFCT and platelet counts (*r* = −0.002, *P* = 0.98) \[[Figure 2b](#F2){ref-type="fig"}\]. There was no correlation between IOP and platelet counts (*r* = −0.06, *P* = 0.65) \[[Figure 2c](#F2){ref-type="fig"}\]. [Figure 3](#F3){ref-type="fig"} demonstrates the box plot graphics of RAC (A) and RVC (B) in the study and control groups.

![Scatter plot graphics showing the correlation between ocular pulse amplitude and blood platelet counts (a), subfoveal choroidal thickness and blood platelet counts (b), and intraocular pressure and blood platelet counts (c)](MEAJO-23-84-g004){#F2}

![Box plot graphics showing the retinal arteriolar (a) and venular (b) caliber (μm) ranges of the essential thrombocythemia group and control group](MEAJO-23-84-g005){#F3}

The mean RAC value was 88.5 ± 5.7 µm in the study group, and 95.5 ± 4.8 µm in the control group (*P* \< 0.001). The mean RVC value was 119.6 ± 11.4 µm in the study group, and 125.6 ± 8.6 µm in the control group (*P* = 0.02). There was a significant negative correlation between RAC and platelet counts (*r* = −0.35, *P* = 0.008). RVC was not associated to platelet counts (*r* = 0.10, *P* = 0.44).

DISCUSSION {#sec1-4}
==========

Our results show that OPA and SFCT values do not differ in patients with ET and healthy control patients. Additionally, RAC is markedly thinner in ET. It would be expected that as a systemic blood disease, ET could cause some alterations in the choroid and retina which have significant blood flow. Platelets in ET may aggregate at unpredictable times, regardless of platelet count.[@ref2][@ref11] This condition may create a risk for ocular vascular complications in patients under treatment.

In addition to thromboembolic and hemorrhagic complications, ET, as a myeloproliferative disorder, may rarely evolve into the acute myeloid leukemia.[@ref1][@ref2] It has been reported that leukemias are associated with choroidal infiltration.[@ref12][@ref13][@ref14] Additionally, amaurosis fugax is has been reported in some ET patients that may be due episodic choroidal ischemic attacks.[@ref3] Hence, ET may affect choroidal thickness. However, we did not find a statistically important SFCT alteration in ET patients and this may be interpreted as ET is not associated with gross ischemic or hemorrhagic choroidal events. In other words, choroid may be protected from systemic hematological threats to some extent. Another possible explanation for this condition may be the rapid blood flow rates in the choroid.

OPA is a surrogate for pulsatile choroidal blood flow, is affected by various systemic vascular conditions such as aortic regurgitation, carotid artery stenosis, and water drinking;[@ref15][@ref16][@ref17] on the other hand OPA is not influenced by systemic blood pressure levels.[@ref18] In the present study, OPA was similar in ET patients and healthy controls. Additionally, we did not find an association between OPA and SFCT in the ET patients and the control group. De Moraes *et al*. reported a strong positive correlation between OPA and choroidal thickness during the water drinking test.[@ref19]

Influence of hematological disorders on IOP has been investigated in several studies.[@ref20][@ref21][@ref22] Yoshizumi and Townsend-Pico reported a case of neovascular glaucoma secondary to central retinal vein occlusion in ET.[@ref5] However, the possible impact of ET on IOP, other than neovascularization, is not clear. Additionally, increased oxidative stress in patients with ET was revealed.[@ref23] It is already known that lower systemic antioxidant capacity is involved in the pathogenesis of glaucoma.[@ref24] In this study, we did not find IOP increase in ET.

Retinal vessel caliber measurements show anatomical microcirculation and may reflect the vascular effects of some systemic diseases.[@ref25][@ref26][@ref27] Narrower RAC is associated with older age, systemic arterial hypertension, and coronary heart disease.[@ref26][@ref27] Wider RVC is associated with diabetes mellitus, lipid disorders, cigarette smoking, and coronary heart disease.[@ref26][@ref27] In the present study, ET was associated with narrower RAC and RVC. Similar to our results, Liew *et al*. found that blood platelet count is associated with narrower RAC;[@ref28] but apart from our results they found that blood platelet count is associated with wider RVC. The difference in RVC measurements may be due the many pathological aspects of ET and just increased platelet count.

Our study has several limitations. One limitation was the inability to perform the measurements in active and untreated disease status because all of the patients were taking medications for ET. However, it was shown that the vascular complications of ET could occur in normal platelet counts, regardless of the disease activity.[@ref29] Another limitation is the lack of retina-choroidal Doppler ultrasound investigation that might support our findings.

CONCLUSION {#sec1-5}
==========

ET does not cause anatomical or physiological alterations in the choroid. But RAC is negatively correlated with blood platelet counts and decreased in ET. Our results may indicate that choroid has strong autoregulatory mechanisms for countering blood platelet aggregation and micro thrombosis. Further studies including indocyanine green and fluorescein angiography examinations may provide additional insight on this topic.
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